Friday, 16 October 2026European Markets

APERAM And AIR LIQUIDE Have A High Dividend Yield And Return On Equity In The Basic Materials Sector.

Loading stream...

(vianews) - aperam (apam.as) is among this list of stock assets with the highest dividend rate and return on equity on the basic materials sector.

financial asset price forward dividend yield return on equity
aperam (apam.as) €31.17 6.34% 5.96%
air liquide (ai.pa) €169.60 1.67% 13.73%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. aperam (apam.as)

6.34% forward dividend yield and 5.96% return on equity

aperam s.a., together with its subsidiaries, engages in the production and sale of stainless and specialty steel products worldwide. it operates through four segments: stainless & electrical steel; services & solutions; alloys & specialties; and recycling & renewables. the company offers range of stainless steel products, including grain oriented and non-grain oriented electrical steel products, and specialty alloys. it is also involved in the distribution of its products; and the provision of transformation services that include value added and customized steel solutions. in addition, the company designs, produces, and transforms various specialty alloys and other specific stainless steels in forms, such as bars, semis, cold-rolled strips, wire and wire rods, and plates in a range on grades. further, it engages in the trading, processing, and recycling of raw materials, such as superalloys and titanium; provides recyco, an electric arc furnace recycling facility that retrieves dust and sludge to recycle stainless steel raw materials and reduce waste; and produces wood and charcoal from cultivated eucalyptus forests. the company serves customers in aerospace, automotive, catering, construction, household appliances, electrical engineering, industrial processes, medical, and oil and gas industries. it distributes its products through a network of steel service centers, transformation facilities, and sales offices. the company was incorporated in 2010 and is headquartered in luxembourg city, luxembourg.

earnings per share

as for profitability, aperam has a trailing twelve months eps of €1.93.

pe ratio

aperam has a trailing twelve months price to earnings ratio of 16.15. meaning, the purchaser of the share is investing €16.15 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.96%.

revenue growth

year-on-year quarterly revenue growth declined by 4%, now sitting on 6.59b for the twelve trailing months.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on feb 27, 2024, the estimated forward annual dividend rate is 2 and the estimated forward annual dividend yield is 6.34%.

moving average

aperam's worth is above its 50-day moving average of €30.73 and above its 200-day moving average of €29.24.

sales growth

aperam's sales growth is negative 6.9% for the ongoing quarter and negative 12.2% for the next.

more news about aperam.

2. air liquide (ai.pa)

1.67% forward dividend yield and 13.73% return on equity

l'air liquide s.a. provides gases, technologies, and services for the industrial and health sectors in europe, the americas, the asia pacific, the middle east, and africa. the gas & services segment comprises large industries business, which offers gas and energy solutions including oxygen, nitrogen, argon, hydrogen, and carbon monoxide, as well as operates cogeneration plants to supply steam and electricity to metals, chemicals, refining, and energy industries; and industrial merchant business line provides industrial gases, equipment, hardgoods, and associated services to material and energy, automotive and manufacturing, food and pharmaceuticals, technology and research, and craftsmen and retail sector. this segment also includes healthcare business, which provides medical gases, home healthcare services, medical equipment, and specialty ingredient to patients, healthcare professionals, and hospitals; and electronic business supply carrier gases, electronic specialty and advanced materials, equipment and installation, and service to semiconductor, flat panel, and photovoltaic markets. its engineering & construction segment designs, develops, and builds industrial gas production plants to third parties; and design and manufacture plants in traditional, renewable and alternative energy sectors. the global markets & technologies segment delivers technological solutions, such as molecules, equipment, and services to energy transition, primarily in transport, energy, and waste valorization, as well as space exploration, aerospace, fundamental sciences, and quantum computing. this segment also invests in biomethane production units; develops stations for distributing natural biogas for vehicles and hydrogen; operates biomethane production units for maritime industry; and supplies gases for the offshore oil and gas platforms, offshore wind turbines, and cryogenic transportation by sea. l'air liquide s.a. was incorporated in 1902 and is headquartered in paris, france.

earnings per share

as for profitability, air liquide has a trailing twelve months eps of €6.07.

pe ratio

air liquide has a trailing twelve months price to earnings ratio of 27.94. meaning, the purchaser of the share is investing €27.94 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.73%.

moving average

air liquide's value is higher than its 50-day moving average of €169.37 and higher than its 200-day moving average of €162.42.

revenue growth

year-on-year quarterly revenue growth declined by 1.6%, now sitting on 29.71b for the twelve trailing months.

more news about air liquide.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com